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Introduction
Factors that would predict treatment outcome for meth-
otrexate (MTX) would be of great value to clinicians.
Recent pharmacogenetic studies have reported associa-
tions between single nucleotide polymorphisms (SNP) in
MTX transporters and treatment outcome in childhood
acute lymphoblastic leukemia and in rheumatoid arthritis.
Objectives
To investigate the influence of SNP in the genes for MTX
uptake and efflux transporters on toxicity and response
to therapy in JIA.
Methods
The data of 77 consecutive patients with JIA treated with
MTX at the University Children’s Hospital Ljubljana from
June 2011 to February 2013 have been retrospectively
reviewed. The disease activity was measured by JADAS 71
score 3 and 6 months after the beginning of treatment
with MTX and at the last follow up visit. All adverse
events were noted separately for different organ systems.
Genotyping of single nucleotide polymorphisms (SNP) in
the genes of MTX transporters was performed using real
time PCR methods. The analysed SNPs were: ABCB1
3435C>T (rs1045642), ABCC2 24C>T (rs717620), ABCC2
1019A>G (rs2804402), ABCC2 1249G>A (rs2273697),
ABCG2 34G>A (rs2231137), ABCG2 421C>A (rs
2231142), SLCO1B1 174Ala>Val (rs4149056), SLCO1B1
388 A>G (rs2306283), SLCO1B1 int13 T>C (rs11045879)
and SLC19A1 (RFC1) 80G>A (rs1051266). Chi-square test
and logistic regression were used for the statistical
analysis.
Results
The study group included 54 girls (70%) and 23 boys
(30%) with JIA with mean disease duration 63 months.
Nine (12%) patients had systemic arthritis, 23 (30%)
patients had polyarthritis (4 out of these were RF posi-
tive), 15 (19%) patients had persistent oligoarthritis, 14
(18%) extended oligoarthritis, 10 (13%) patients had
juvenile psoriatic arthritis and one (1%) patient suffered
from enthesitis related arthritis. Five (6%) patients were
treated with MTX because of chronic idiopathic uveitis.
Mean follow up time was 80 months. Thirteen out of
77 (17%) patients were in remission without therapy at
the last follow up visit. In total 37 out of 77 patients
(48%) had to be switched to biologic therapy due to
treatment inefficacy or severe adverse events. Adverse
events developed in 47 patients (61%), 11 patients (14%)
had severe adverse events and 9 patients (12%) discon-
tinued MTX treatment because of adverse events.
SLCO1B1 174Ala>Val (p = 0.059), ABCB1 3435C>T
(p = 0.063 OR:3.065, 95%CI:0.908-10.338) and ABCC2
1019A>G (p = 0.113, OR:3.592, 95% CI: 0.739-17.461)
showed a trend for association with gastrointestinal
adverse events. ABCG2 34G>A (p = 0.054) and SLC19A1
80G>A (p = 0.078) were marginally associated with
dermatological adverse events, while ABCG2 34G>A
showed association with infections (p = 0.049 OR:5.158,
95%CI: 0.871-30.528).
Conclusion
We reported for the first time the influence of SLCO1B1
on MTX treatment toxicity in JIA. SNPs in MTX trans-
porters’ genes may be a useful tool to predict toxicity in
patients with JIA treated with MTX, but replications of
our study in larger groups of patients are needed.
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